Abstract
Recently, a mechanism of negative regulation of immune responses by a specialized population of so-called regulatory T cells (Tregs) has become a focus of intense investigation. Through the discovery of transcription factor Foxp3 as a central molecular determinant of Tregs differentiation and function, the complex biology of these cells, including maintenance of immunological tolerance to “self” and regulation of immune responses to pathogens, commensals, and tumors, has become the focus of intense investigation. The ability to control the infection and to delay the progression of the infection to AIDS and/or death is probably regulated by a balance between host factors, such as immunologic response and viral factors. Different rates of disease progression among HIV-1 infected individuals have been observed. In this context, Tregs may play an important role in the immunopathology of HIV-1 infection due to their potent suppressive activity of both T cell activation and effector function. In this review, we present the molecular and immunological aspects of Tregs in the HIV system and the association between Tregs and highly active antiretroviral therapy (HAART).
Keywords: Regulatory T cells, HIV, Foxp3, highly active antiretroviral therapy
Current HIV Research
Title: Involvement of Regulatory T Cells in HIV Immunopathogenesis
Volume: 8 Issue: 4
Author(s): Sara S. Bernardes, Isabele K. Borges, Juliana E. Lima, Paula de Azevedo O. Milanez, Ivete Conchon-Costa, Ionice Felipe, Halha O. Saridakis and Maria A.E. Watanabe
Affiliation:
Keywords: Regulatory T cells, HIV, Foxp3, highly active antiretroviral therapy
Abstract: Recently, a mechanism of negative regulation of immune responses by a specialized population of so-called regulatory T cells (Tregs) has become a focus of intense investigation. Through the discovery of transcription factor Foxp3 as a central molecular determinant of Tregs differentiation and function, the complex biology of these cells, including maintenance of immunological tolerance to “self” and regulation of immune responses to pathogens, commensals, and tumors, has become the focus of intense investigation. The ability to control the infection and to delay the progression of the infection to AIDS and/or death is probably regulated by a balance between host factors, such as immunologic response and viral factors. Different rates of disease progression among HIV-1 infected individuals have been observed. In this context, Tregs may play an important role in the immunopathology of HIV-1 infection due to their potent suppressive activity of both T cell activation and effector function. In this review, we present the molecular and immunological aspects of Tregs in the HIV system and the association between Tregs and highly active antiretroviral therapy (HAART).
Export Options
About this article
Cite this article as:
S. Bernardes Sara, K. Borges Isabele, E. Lima Juliana, de Azevedo O. Milanez Paula, Conchon-Costa Ivete, Felipe Ionice, O. Saridakis Halha and A.E. Watanabe Maria, Involvement of Regulatory T Cells in HIV Immunopathogenesis, Current HIV Research 2010; 8 (4) . https://dx.doi.org/10.2174/157016210791208613
DOI https://dx.doi.org/10.2174/157016210791208613 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ipilimumab and Vemurafenib: Two Different Routes for Targeting Melanoma
Current Cancer Drug Targets Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Clinical Next Generation Sequencing for Precision Medicine in Cancer
Current Genomics Glycosides from Medicinal Plants as Potential Anticancer Agents: Emerging Trends Towards Future Drugs
Current Medicinal Chemistry Airway Smooth Muscle Responsiveness: The Origin of Airway Hyperresponsiveness in Asthma?
Current Respiratory Medicine Reviews The S100A8 and S100A9 Proteins are Attractive Targets to Modulate Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Recent Advances in the Development of Immunoadhesins for Immune Therapy and as Anti-Infective Agents
Recent Patents on Anti-Infective Drug Discovery Biodegradable Nanoparticles: A Recent Approach and Applications
Current Drug Targets Quinoline-3-carboxylate Derivatives: A New Hope as an Antiproliferative Agent
Anti-Cancer Agents in Medicinal Chemistry Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design Current Prodrug Strategies for the Delivery of Nucleotides into Cells
Drug Design Reviews - Online (Discontinued) Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Biotherapy for Autoimmune Liver Diseases
Current Pharmaceutical Biotechnology Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery
Current Drug Targets Domperidone and Long QT Syndrome
Current Drug Safety